CytoDyn Inc. (CYDY)
OTC Markets OTCQB · USD · Healthcare · Biotechnology
$0.24 (-7.69%) as of
Key statistics
- Market cap
- 352.68M
- Forward P/E
- -1.33
- EPS (TTM)
- -0.0300
- Dividend yield
- 0.00%
- 52-week range
- 0.1800 – 0.4000
- Beta
- 1.50
- Profit margin
- 0.00%
- Volume
- 2.75M
About CytoDyn Inc.
CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. The company develops leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. Its leronlimab completed phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Vancouver, WA, United States
- Employees
- 14
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.